These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

140 related articles for article (PubMed ID: 8453963)

  • 1. Pharmacodynamic model of the haemodynamic effects of pinacidil in normotensive volunteers.
    Girard P; Saumet JL; Dubois F; Boissel JP
    Eur J Clin Pharmacol; 1993; 44(2):177-82. PubMed ID: 8453963
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Pharmacodynamics and pharmacokinetics of pinacidil after a single dose of a new slow release tablet in healthy volunteers.
    Bareggi SR; Gambaro V; Valenti M; Benvenuti C
    Arzneimittelforschung; 1998 Jul; 48(7):730-3. PubMed ID: 9706373
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Pharmacokinetic-pharmacodynamic modeling between pinacidil or pinacidil-N-oxide plasma levels and systemic and regional hemodynamic effects in healthy volunteers.
    Bellissant E; Chau NP; Thuillez C; Giudicelli JF
    Fundam Clin Pharmacol; 1994; 8(5):437-45. PubMed ID: 7875638
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Acute haemodynamic effects of pinacidil in man.
    Nicholls DP; Murtagh JG; Scott ME; Morton P; Shanks RG
    Br J Clin Pharmacol; 1986 Sep; 22(3):287-92. PubMed ID: 3768241
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Pharmacokinetics and hypotensive effect in healthy volunteers of pinacidil, a new potent vasodilator.
    Ward JW; McBurney A; Farrow PR; Sharp P
    Eur J Clin Pharmacol; 1984; 26(5):603-8. PubMed ID: 6468476
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Modeling of the pharmacokinetic/pharmacodynamic interaction between irbesartan and hydrochlorothiazide in normotensive subjects.
    Hedaya MA; Helmy SA
    Biopharm Drug Dispos; 2015 May; 36(4):216-31. PubMed ID: 25545238
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Actions of pinacidil at a reduced potassium concentration: a direct cardiac effect possibly involving the ATP-dependent potassium channel.
    Chi L; Black SC; Kuo PI; Fagbemi SO; Lucchesi BR
    J Cardiovasc Pharmacol; 1993 Feb; 21(2):179-90. PubMed ID: 7679150
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Acute hemodynamic effects of pinacidil in hypertensive patients with and without propranolol pretreatment.
    Stone CK; Wellington KL; Willick A; Sullebarger JT; Liang CS
    J Clin Pharmacol; 1991 Apr; 31(4):333-41. PubMed ID: 2037705
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Clinical pharmacokinetics of pinacidil, a potassium channel opener, in hypertension.
    Goldberg MR; Rockhold FW; Thompson WL; DeSante KA
    J Clin Pharmacol; 1989 Jan; 29(1):33-40. PubMed ID: 2708546
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Pharmacokinetics and pharmacodynamic effects of the angiotensin II antagonist valsartan at steady state in healthy, normotensive subjects.
    Müller P; Flesch G; de Gasparo M; Gasparini M; Howald H
    Eur J Clin Pharmacol; 1997; 52(6):441-9. PubMed ID: 9342579
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Pharmacodynamics and pharmacokinetics of pinacidil in normotensive volunteers after repeated doses of a new slow-release tablet formulation.
    Bareggi SR; Gambaro V; Valenti M; Benvenuti C
    Arzneimittelforschung; 1999 Jan; 49(1):21-5. PubMed ID: 10028374
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Pharmacokinetic-pharmacodynamic (PK-PD) modeling for a new antihypertensive agent (neutral metalloendopeptidase inhibitor SCH 42354) in patients with mild to moderate hypertension.
    Fettner SH; Pai S; Zhu GR; Kosoglou T; Banfield CR; Batra V
    Eur J Clin Pharmacol; 1995; 48(5):351-9. PubMed ID: 8641322
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Double-blind comparator trials with pinacidil, a potassium channel opener.
    Callaghan JT; Goldberg MR; Brunelle R
    Drugs; 1988; 36 Suppl 7():77-82. PubMed ID: 3076139
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Pinacidil. Preclinical investigations.
    Ahnfelt-Rønne I
    Drugs; 1988; 36 Suppl 7():4-9. PubMed ID: 3076134
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Systemic and coronary hemodynamic effects of pinacidil, a new antihypertensive agent, in awake dogs: comparison with hydralazine.
    Kawashima S; Liang CS
    J Pharmacol Exp Ther; 1985 Feb; 232(2):369-75. PubMed ID: 3968638
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Hemodynamic and myocardial blood flow. Profiles of pinacidil and nitroprusside in conscious dogs.
    Dubé GP; Greenfield JC
    Am J Hypertens; 1991 Feb; 4(2 Pt 1):144-50. PubMed ID: 2021445
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Pinacidil. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic potential in the treatment of hypertension.
    Friedel HA; Brogden RN
    Drugs; 1990 Jun; 39(6):929-67. PubMed ID: 2196168
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Clinical pharmacology of pinacidil, a prototype for drugs that affect potassium channels.
    Goldberg MR
    J Cardiovasc Pharmacol; 1988; 12 Suppl 2():S41-7. PubMed ID: 2466178
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Effect of pinacidil on renal haemodynamics, tubular function and plasma levels of angiotensin II, aldosterone and atrial natriuretic peptide in healthy man.
    Nielsen CB; Pedersen EB
    Eur J Clin Pharmacol; 1993; 45(1):29-35. PubMed ID: 8405026
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Pinacidil, a new vasodilator: pharmacokinetics and pharmacodynamics of a new retarded release tablet in essential hypertension.
    Carlsen JE; Kardel T; Jensen HA; Tangø M; Trap-Jensen J
    Eur J Clin Pharmacol; 1983; 25(4):557-61. PubMed ID: 6653652
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.